Zymeworks (NYSE:ZYME - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Parties interested in participating in the company's conference call can do so using this link.
Zymeworks (NYSE:ZYME - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The business had revenue of $19.24 million for the quarter, compared to the consensus estimate of $23.16 million. Zymeworks had a negative net margin of 179.42% and a negative return on equity of 21.97%. During the same quarter in the previous year, the firm earned ($0.76) earnings per share. On average, analysts expect Zymeworks to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Zymeworks Stock Performance
Shares of NYSE ZYME traded down $0.19 during midday trading on Thursday, reaching $12.92. The stock had a trading volume of 247,141 shares, compared to its average volume of 625,445. Zymeworks has a 12-month low of $6.51 and a 12-month high of $14.05. The company has a market capitalization of $917.97 million, a price-to-earnings ratio of -8.63 and a beta of 1.20. The stock has a 50-day moving average of $12.23 and a 200-day moving average of $10.26.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ZYME. Stifel Nicolaus upped their price objective on Zymeworks from $20.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. HC Wainwright reiterated a "neutral" rating and issued a $12.00 price target on shares of Zymeworks in a report on Tuesday.
Read Our Latest Analysis on Zymeworks
About Zymeworks
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Articles
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
